Update on Woulgan® distribution agreement processes

(Tromsø, 7th July 2015) Biotec Pharmacon ASA (”Biotec”, OSE: BIOTEC) and Smith & Nephew have today mutually decided to end the discussion about a Woulgan® distribution agreement. Consequently, Biotec will therefore accelerate the on-going process to pursue an alternative market channel strategy, which would include distribution agreements with strong regional business partners and distributors.

– Following a period of thorough and constructive discussion with Smith & Nephew, the parties have concluded not to enter into an exclusive commercial agreement for … continue reading »

ArcticZymes granted further patent protection on its heat-labile dsDNase product in the USA

ArcticZymes AS, a subsidiary of Biotec Pharmacon ASA, has received a Notice of Allowance for the United States Patent Application No. 14/036459 further covering patentable subject matter of its heat-labile dsDNase product.

With the approval of the new patent in the USA, ArcticZymes strengthens its rapidly growing intellectual property portfolio. The patent extends protection in the USA to the nucleic acid sequence of the heat-labile dsDNase. This includes a method of isolation and purification of the expressed sequence and subsequent incorporation … continue reading »

Data from Norwegian survey study on Woulgan® being presented at EWMA, London May 2015

Biotec Pharmacon ASA (OSX: BIOTEC) reports that the novel wound management product Woulgan® has been tested on different types of hard-to-heal wounds in a Norwegian study with very promising results. The gel product, Woulgan,® contains the company’s proprietary macrophage activating agent SBG® as an ancillary medicinal component. Woulgan® is primarily developed for management of hard-to-heal wounds like diabetic ulcers (DU), leg ulcers (LU) and pressure ulcers (PU). The Health Care Professionals testing Woulgan® reported very high satisfaction with both the … continue reading »

Webcast: Presentation of Q1-2015

Biotec Pharmacon presents its interim report for the first quarter 2015 on Tuesday, 5 May at 08:30. The presentation will be held as a live video webcast produced by Hegnar TV. The presentation will be given in Norwegian by CEO Svein Lien.

Venue: Felix Konferansesenter, Bryggetorget 3, Oslo.

It will be possible to submit questions to the speaker through the webcast console at the end of the presentation.

Watch the presentation here

Notice of Annual General Meeting 2015

The Annual General Meeting in Biotec Pharmacon ASA will be held 12 May 2015 at 12:00 in Tromsø.

The notice with the complete agenda has been distributed by mail to shareholders registered as of 17 April 2015.

Download documents regarding the General Meeting here.
Download Annual Report 2015 (N) here.